Přispěvatelé: |
[Pérez-Ruiz,E, Gutiérrez,V, Muñoz,M, Gálvez-Carvajal,L, Rueda-Domínguez,A] Unidad de Gestión Clínica Intercentros de Oncología Médica, Oncology Department, Institute of Biomedical Investigation of Malaga (IBIMA), Hospitales Universitarios Regional y Virgen de la Victoria, Malaga, Spain. [Oliver,J, Barragán,I] Researcher Unit, Unidad de Gestión Clínica Intercentros de Oncología Médica, Institute of Biomedical Investigation of Malaga (IBIMA), Hospitales Universitarios Regional y Virgen de la Victoria, Malaga, Spain. [Sánchez,M] Maxillofacial Surgery Department, Hospital Regional Universitario de Málaga, Málaga, Spain. [Barragán,I] Group of Pharmacoepigenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, E.P.-R. has received a grant from The Spanish Society of Medical Oncology (SEOM). IB has received funding (project SA 0263/2017, Nicolás Monardes Program) from the Consejería de Salud y Familias, Junta de Andalucía, Spain. |
Popis: |
Oral squamous cell carcinoma (OSCC) constitutes approximately 25% of all head and neck cancer, for which the consumption of tobacco and alcohol are the main associated risk factors. The field cancerization effect of OSCC is one of the main reasons for the poor survival rates associated with this disease. Despite some advances, its ccharacterization and early diagnosis continue to challenge modern oncology, and the goal of improving the prognosis remains to be achieved. Among new early diagnostic tools for OSCC that have been proposed, liquid biopsy appears to be an ideal candidate, as studies have shown that the analysis of blood and saliva provides promising data for the early detection of relapses or second tumours. Yes |